William Blair Expects Stronger Earnings for Simulations Plus

Simulations Plus, Inc. (NASDAQ:SLP) – Equities research analysts at William Blair boosted their FY2026 earnings estimates for shares of Simulations Plus in a research report issued on Tuesday, December 2nd. William Blair analyst M. Smock now anticipates that the technology company will post earnings of $1.04 per share for the year, up from their previous forecast of $1.03. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q1 2027 earnings at $0.23 EPS, Q2 2027 earnings at $0.29 EPS, Q3 2027 earnings at $0.33 EPS and Q4 2027 earnings at $0.36 EPS.

SLP has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, October 28th. TD Cowen assumed coverage on shares of Simulations Plus in a research note on Tuesday, September 30th. They issued a “hold” rating and a $16.00 target price for the company. KeyCorp restated a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. Finally, Cowen assumed coverage on Simulations Plus in a report on Tuesday, September 30th. They issued a “hold” rating for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.40.

Simulations Plus Trading Up 0.7%

Shares of Simulations Plus stock opened at $20.49 on Wednesday. Simulations Plus has a 1 year low of $12.39 and a 1 year high of $37.67. The company’s fifty day simple moving average is $16.84 and its 200-day simple moving average is $17.59. The company has a market cap of $412.87 million, a price-to-earnings ratio of -6.36 and a beta of 1.16.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Monday, December 1st. The technology company reported $0.10 EPS for the quarter, hitting the consensus estimate of $0.10. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.The company had revenue of $17.46 million for the quarter, compared to the consensus estimate of $17.41 million. During the same period in the previous year, the business posted $0.06 EPS.

Hedge Funds Weigh In On Simulations Plus

Several institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new stake in Simulations Plus in the 1st quarter valued at about $2,458,000. Charles Schwab Investment Management Inc. lifted its position in shares of Simulations Plus by 16.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 166,392 shares of the technology company’s stock worth $4,080,000 after purchasing an additional 23,139 shares in the last quarter. Comerica Bank grew its stake in shares of Simulations Plus by 16.6% during the first quarter. Comerica Bank now owns 193,990 shares of the technology company’s stock valued at $4,757,000 after purchasing an additional 27,579 shares during the last quarter. Versor Investments LP bought a new stake in shares of Simulations Plus during the second quarter valued at approximately $496,000. Finally, Kopion Asset Management LLC increased its holdings in shares of Simulations Plus by 22.7% in the second quarter. Kopion Asset Management LLC now owns 156,401 shares of the technology company’s stock valued at $2,729,000 after purchasing an additional 28,980 shares in the last quarter. 78.08% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.